Novo, Novartis and Amgen all recorded exits as blood disorder therapeutics developer Ra floated in the middle of its range.
Ra Pharmaceuticals, a US-based developer of rare blood disorder treatments, raised $91.6m yesterday in an initial public offering that gave exits to pharmaceutical firms Novo, Novartis and Amgen.
The company priced just over 7 million shares at $13 each, in the middle of the $12 to $14 range it set last week. In its first day of trading on Nasdaq Ra’s shares briefly rose as high as $14.86 before closing back at $13.00.
Ra is developing drugs to…
